{
    "id": 90,
    "premise": "none",
    "hypothesis": "Olaparib and talazoparib are licensed PARP inhibitors, which target tumour specific defects in DNA repair.",
    "label": "entailment",
    "explanation": "[PARP1/2] inhibitors target tumour-specific defects in DNA repair through the role of PARP1/2 in recover from DNA damage.\nolaparib and talazoparib are licensed poly [ADP-ribose] polymerase 1/2 inhibitors.",
    "results": {
        "semantic validity": true,
        "premise": null,
        "hypothesis": "Olaparib and talazoparib are licensed PARP inhibitors, which target tumour specific defects in DNA repair.",
        "refined explanation": "[PARP1/2] inhibitors target tumour-specific defects in DNA repair through the role of PARP1/2 in recover from DNA damage.\nolaparib and talazoparib are licensed poly [ADP-ribose] polymerase 1/2 inhibitors.",
        "refined iteration": 0,
        "history explanation": [
            "0 iteration: [PARP1/2] inhibitors target tumour-specific defects in DNA repair through the role of PARP1/2 in recover from DNA damage.\nolaparib and talazoparib are licensed poly [ADP-ribose] polymerase 1/2 inhibitors."
        ],
        "history semantic validity": [
            "0 iteration: True"
        ],
        "history critique output": [
            "0 iteration: {'syntactic validity': True, 'error code': '', 'solving time': 21.848974466323853, 'proof tactics': ['Sledgehammering...', 'zipperposition found a proof...', 'cvc4 found a proof...', 'vampire found a proof...', 'e found a proof...', 'e: Try this: using assms explanation_1 by blast (4 ms)', 'cvc4 found a proof...', 'zipperposition: Found duplicate proof', 'cvc4: Found duplicate proof', 'vampire: Found duplicate proof', 'cvc4: Found duplicate proof', 'Done'], 'code': 'theory clinical_90_0\\nimports Main\\n\\nbegin\\n\\ntypedecl entity\\ntypedecl event\\n\\nconsts\\n  PARP1_2Inhibitor :: \"entity \u21d2 bool\"\\n  TumourSpecificDefects :: \"entity \u21d2 bool\"\\n  DNARepair :: \"entity \u21d2 bool\"\\n  Target :: \"event \u21d2 bool\"\\n  Agent :: \"event \u21d2 entity \u21d2 bool\"\\n  Patient :: \"event \u21d2 entity \u21d2 bool\"\\n  Role :: \"entity \u21d2 bool\"\\n  PARP1_2 :: \"entity \u21d2 bool\"\\n  RecoverFromDNADamage :: \"entity \u21d2 bool\"\\n  Olaparib :: \"entity \u21d2 bool\"\\n  Talazoparib :: \"entity \u21d2 bool\"\\n  PolyADPRibosePolymerase1_2Inhibitor :: \"entity \u21d2 bool\"\\n  Licensed :: \"entity \u21d2 bool\"\\n  PARPInhibitor :: \"entity \u21d2 bool\"\\n\\n(* Explanation 1: [PARP1/2] inhibitors target tumour-specific defects in DNA repair through the role of PARP1/2 in recover from DNA damage. *)\\naxiomatization where\\n  explanation_1: \"\u2200x y z e. PARP1_2Inhibitor x \u2227 TumourSpecificDefects y \u2227 DNARepair y \u2227 Target e \u2227 Agent e x \u2227 Patient e y \u2227 Role z \u2227 PARP1_2 z \u2227 RecoverFromDNADamage z\"\\n\\n(* Explanation 2: Olaparib and talazoparib are licensed poly [ADP-ribose] polymerase 1/2 inhibitors. *)\\naxiomatization where\\n  explanation_2: \"\u2200x y. (Olaparib x \u2228 Talazoparib x) \u2227 PolyADPRibosePolymerase1_2Inhibitor y \u2227 Licensed y\"\\n\\ntheorem hypothesis:\\n  assumes asm: \"(Olaparib x \u2228 Talazoparib x) \u2227 PARPInhibitor y \u2227 Licensed y\"\\n  (* Hypothesis: Olaparib and talazoparib are licensed PARP inhibitors, which target tumour specific defects in DNA repair. *)\\n  shows \"\u2203x y z e. (Olaparib x \u2228 Talazoparib x) \u2227 PARPInhibitor y \u2227 Licensed y \u2227 Target e \u2227 Agent e y \u2227 Patient e z \u2227 TumourSpecificDefects z \u2227 DNARepair z\"\\nproof -\\n  (* From the premise, we have information about Olaparib or Talazoparib being licensed PARP inhibitors. *)\\n  from asm have \"(Olaparib x \u2228 Talazoparib x) \u2227 PARPInhibitor y \u2227 Licensed y\" <ATP>\\n  (* Explanation 2 states that Olaparib and Talazoparib are licensed poly [ADP-ribose] polymerase 1/2 inhibitors. *)\\n  (* This implies they are also PARP1/2 inhibitors, which target tumour-specific defects in DNA repair. *)\\n  (* Explanation 1 provides the necessary link between PARP1/2 inhibitors and targeting tumour-specific defects in DNA repair. *)\\n  (* Therefore, we can infer the existence of an event where these inhibitors target tumour-specific defects in DNA repair. *)\\n  then have \"\u2203x y z e. (Olaparib x \u2228 Talazoparib x) \u2227 PARPInhibitor y \u2227 Licensed y \u2227 Target e \u2227 Agent e y \u2227 Patient e z \u2227 TumourSpecificDefects z \u2227 DNARepair z\" <ATP>\\n  then show ?thesis <ATP>\\nqed\\n\\nend\\n', 'logical information': 'Logical Propositions:\\nA: [PARP1/2] inhibitors target tumour-specific defects in DNA repair (from Explanatory Sentence 1)\\nB: PARP1/2 is involved in recovery from DNA damage (from Explanatory Sentence 1)\\nC: olaparib is a poly [ADP-ribose] polymerase 1/2 inhibitor (from Explanatory Sentence 2)\\nD: talazoparib is a poly [ADP-ribose] polymerase 1/2 inhibitor (from Explanatory Sentence 2)\\n\\nLogical Relations:\\nImplies(A, B)\\nImplies([PARP1/2] inhibitors target tumour-specific defects in DNA repair, PARP1/2 is involved in recovery from DNA damage)\\n--------\\nAnd(C, D)\\nC & D\\n--------\\n\\nDerived Implications:\\nImplies(Not(A), C)\\nImplies(Not([PARP1/2] inhibitors target tumour-specific defects in DNA repair), olaparib is a poly [ADP-ribose] polymerase 1/2 inhibitor)\\n--------\\nImplies(Not(C), C)\\nImplies(Not(olaparib is a poly [ADP-ribose] polymerase 1/2 inhibitor), olaparib is a poly [ADP-ribose] polymerase 1/2 inhibitor)\\n--------\\nImplies(Not(D), Not(B))\\nImplies(Not(talazoparib is a poly [ADP-ribose] polymerase 1/2 inhibitor), Not(PARP1/2 is involved in recovery from DNA damage))\\n--------\\nImplies(Not(D), D)\\nImplies(Not(talazoparib is a poly [ADP-ribose] polymerase 1/2 inhibitor), talazoparib is a poly [ADP-ribose] polymerase 1/2 inhibitor)\\n--------\\nImplies(Not(D), Not(C))\\nImplies(Not(talazoparib is a poly [ADP-ribose] polymerase 1/2 inhibitor), Not(olaparib is a poly [ADP-ribose] polymerase 1/2 inhibitor))\\n--------\\nImplies(Not(C), Not(B))\\nImplies(Not(olaparib is a poly [ADP-ribose] polymerase 1/2 inhibitor), Not(PARP1/2 is involved in recovery from DNA damage))\\n--------\\nImplies(Not(A), D)\\nImplies(Not([PARP1/2] inhibitors target tumour-specific defects in DNA repair), talazoparib is a poly [ADP-ribose] polymerase 1/2 inhibitor)\\n--------\\nImplies(Not(C), D)\\nImplies(Not(olaparib is a poly [ADP-ribose] polymerase 1/2 inhibitor), talazoparib is a poly [ADP-ribose] polymerase 1/2 inhibitor)\\n--------\\nImplies(Not(D), B)\\nImplies(Not(talazoparib is a poly [ADP-ribose] polymerase 1/2 inhibitor), PARP1/2 is involved in recovery from DNA damage)\\n--------\\nImplies(Not(D), Not(A))\\nImplies(Not(talazoparib is a poly [ADP-ribose] polymerase 1/2 inhibitor), Not([PARP1/2] inhibitors target tumour-specific defects in DNA repair))\\n--------\\nImplies(Not(C), Not(D))\\nImplies(Not(olaparib is a poly [ADP-ribose] polymerase 1/2 inhibitor), Not(talazoparib is a poly [ADP-ribose] polymerase 1/2 inhibitor))\\n--------\\nImplies(Not(C), B)\\nImplies(Not(olaparib is a poly [ADP-ribose] polymerase 1/2 inhibitor), PARP1/2 is involved in recovery from DNA damage)\\n--------\\nImplies(Not(C), Not(A))\\nImplies(Not(olaparib is a poly [ADP-ribose] polymerase 1/2 inhibitor), Not([PARP1/2] inhibitors target tumour-specific defects in DNA repair))\\n--------\\nImplies(C, D)\\nImplies(olaparib is a poly [ADP-ribose] polymerase 1/2 inhibitor, talazoparib is a poly [ADP-ribose] polymerase 1/2 inhibitor)\\n--------\\nImplies(B, C)\\nImplies(PARP1/2 is involved in recovery from DNA damage, olaparib is a poly [ADP-ribose] polymerase 1/2 inhibitor)\\n--------\\nImplies(A, C)\\nImplies([PARP1/2] inhibitors target tumour-specific defects in DNA repair, olaparib is a poly [ADP-ribose] polymerase 1/2 inhibitor)\\n--------\\nImplies(Not(D), A)\\nImplies(Not(talazoparib is a poly [ADP-ribose] polymerase 1/2 inhibitor), [PARP1/2] inhibitors target tumour-specific defects in DNA repair)\\n--------\\nImplies(B, D)\\nImplies(PARP1/2 is involved in recovery from DNA damage, talazoparib is a poly [ADP-ribose] polymerase 1/2 inhibitor)\\n--------\\nImplies(Not(C), A)\\nImplies(Not(olaparib is a poly [ADP-ribose] polymerase 1/2 inhibitor), [PARP1/2] inhibitors target tumour-specific defects in DNA repair)\\n--------\\nImplies(A, D)\\nImplies([PARP1/2] inhibitors target tumour-specific defects in DNA repair, talazoparib is a poly [ADP-ribose] polymerase 1/2 inhibitor)\\n--------\\nImplies(Not(B), C)\\nImplies(Not(PARP1/2 is involved in recovery from DNA damage), olaparib is a poly [ADP-ribose] polymerase 1/2 inhibitor)\\n--------\\nImplies(Not(B), D)\\nImplies(Not(PARP1/2 is involved in recovery from DNA damage), talazoparib is a poly [ADP-ribose] polymerase 1/2 inhibitor)\\n--------\\nImplies(D, C)\\nImplies(talazoparib is a poly [ADP-ribose] polymerase 1/2 inhibitor, olaparib is a poly [ADP-ribose] polymerase 1/2 inhibitor)\\n--------\\nImplies(Not(D), C)\\nImplies(Not(talazoparib is a poly [ADP-ribose] polymerase 1/2 inhibitor), olaparib is a poly [ADP-ribose] polymerase 1/2 inhibitor)\\n--------\\n'}"
        ]
    }
}